Zilucoplan
Sponsors
Ra Pharmaceuticals, Merit E. Cudkowicz, MD, Amgen, UCB Biopharma SRL
Conditions
Amyotrophic Lateral SclerosisCOVID-19Generalized Myasthenia GravisHealthy ParticipantsHealthy VolunteersImmune Mediated Necrotizing Myopathy
Phase 1
A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
CompletedNCT06511076
Start: 2024-08-05End: 2024-11-26Updated: 2026-01-06
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
RecruitingNCT06961747
Start: 2025-07-09End: 2027-03-23Target: 15Updated: 2026-03-24
Phase 2
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
TerminatedNCT04025632
Start: 2019-11-07End: 2021-06-14Updated: 2022-07-27
HEALEY ALS Platform Trial - Master Protocol
RecruitingNCT04297683
Start: 2020-06-14End: 2028-08-01Target: 1500Updated: 2026-03-27
HEALEY ALS Platform Trial - Regimen A Zilucoplan
CompletedNCT04436497
Start: 2020-07-29End: 2022-05-04Updated: 2023-07-25
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
RecruitingNCT06055959
Start: 2024-10-16End: 2026-12-25Target: 8Updated: 2026-03-27
Phase 3
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
CompletedNCT04590586
Start: 2020-11-24End: 2021-08-03Updated: 2022-06-29
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Enrolling by invitationNCT06435312
Start: 2024-11-19End: 2027-11-19Target: 8Updated: 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
CompletedNCT06471361
Start: 2024-08-27End: 2025-02-03Updated: 2026-03-27